Gynecology Team of WHZJU Attends the 11th Congress of the Society of Endometriosis and Uterine Disorders (SEUD 2025)

From April 24 to 26, 2025, the 11th Annual Meeting of the Society of Endometriosis and Uterine Disorders (SEUD 2025) was been held in Prague, the capital of the Czech Republic. Held annually, SEUD brings experts together to discuss the newest advances in the diagnosis and treatment of endometriosis and uterine diseases.

The theme of this year's annual meeting is "From Adolescence to Menopause: Modern Management of Endometriosis and Uterine Diseases". The conference agenda covers all issues related to endometriosis and uterine diseases from adolescence to menopause, and invites scholars from China, Italy, France, the United States, Australia and other countries from all over the world who are committed to improving women's health to discuss modern management strategies for endometriosis and uterine diseases, and promote the development of gynecology.

This conference setted up a special session for China and South Korea, where young doctors under the age of 45 from both countries presented the basic and clinical research results of endometriosis and adenomyosis. The conference was co-chaired by Prof. Sun-Wei Guo from the Obstetrics and Gynecology Hospital of Fudan University, Prof. SiHyun Cho (Gangnam Severance Hospital, Yonsei University) and Prof. Sung Hoon Kim (Asan Medical Center, President of the Korean Association of Endomyosis) from Ulsan University. The five Chinese delegates were from Shandong Provincial Hospital, Obstetrics and Gynecology Hospital of Fudan University, Women’s Hospital, School of Medicine, Zhejiang University, International Peace Maternity and Child Health Hospital of Shanghai Jiao Tong University, and Peking University First Hospital.

As a member of the Chinese delegation, Dr. Libo Zhu made a clinical study report entitled "Clinical Efficacy of Dydrogesterone in the Treatment of Endometriosis: A Follow-up Study", and retrospectively analyzed the endometriosis patients who received dydrogesterone for more than 3 months in Women’s Hospital, School of Medicine, Zhejiang University from January 1, 2018 to September 30, 2024 through the electronic medical record system. The basic conditions, medication regimens, cyst size, improvement of dysmenorrhea, liver and kidney function and blood lipids were collected to compare the efficacy of different dydrogesterone regimens for endometriosis. A total of 373 patients were enrolled, of whom 152 had dysmenorrhea. Visual analogue score (VAS) was significantly reduced after dydrogesterone treatment, and VAS scores at  1, 3, and 6 months of treatment were significantly reduced on both D5-D24 (days 5 to 24 of the menstrual cycle) and D15-D24 (days 15 to 24 of the menstrual cycle) dosing regimens. There was no significant difference in the maximum diameter and volume of cysts between the two groups at 0, 3 and 6 months of treatment. There was no significant side effect of dydrogesterone on liver and kidney function and blood lipids. The research results also be presented as an e-poster for the conference to show the research results of our hospital to all attendees. At the same time, hot topics such as single-cell transcriptomics revealing the pathogenesis of endometriosis, laparoscopic and robot-assisted laparoscopic treatment of adenomyosis were discussed, and the young scholars on the scene also benefited a lot under the guidance of the moderators. 

This conference not only updated the participants' knowledge of endometriosis and uterine disorders, inspired gynecologists to pay more attention to the early diagnosis and treatment of endometriosis, but also inspired interdisciplinary collaboration and clinical translational thinking. In the future, we will be driven by technological innovation and centered on the needs of patients to promote the dual improvement of diagnosis and treatment services and scientific research capabilities。